A Phase 1 interventional study of SHJ - Low concentration and SHJ - Mid concentration in Myopia, sponsored by Sunhawk Vision Biotech, Inc.. Completed at 1 site in Taiwan. Open to participants aged 10 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-23.
Sponsored by Sunhawk Vision Biotech, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.
Among the 40 studies in Myopia with a site in Taiwan, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 1, and was the 19th registered.
1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:
Hungkuang University · Sites in Taiwan
Ages 15–22 · Healthy volunteers
Kubota Vision Inc. · Sites in Taiwan
Ages 6–13 · Healthy volunteers
Essilor-Polylite Taiwan Co., Ltd. · Sites in Taiwan
Ages 6–12 · Healthy volunteers
Buddhist Tzu Chi General Hospital · Sites in Taiwan
Ages 8–23
National Taiwan University Hospital · Sites in Taiwan
Ages 6–10
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 10 Years to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 65 across the 31 interventional studies, 100 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Sunhawk Vision Biotech, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Sunhawk Vision Biotech, Inc. has 2 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myopia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07345416Menicon Co., Ltd.A Clinical Trial Assessing the Efficacy and Safety of ST-1 Silicone Hydrogel Daily Disposable Soft Contact Lenses Compared to Miru 1day UpSide | 2026-12-31 |
| NCT07107646National Taiwan University HospitalExploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Myopia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, open-label, first-in-human dose-escalation study of SHJ002 Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional children will receive the highest tolerated concentration for 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
0.025% SHJ002 Sterile Ophthalmic Solution
Drug: SHJ - Low concentration
0.080% SHJ002 Sterile Ophthalmic Solution
Drug: SHJ - Mid concentration
0.25% SHJ002 Sterile Ophthalmic Solution
Drug: SHJ - High concentration
Maximum tolerated concentration of SHJ002
Drug: SHJ - Maximum tolerated
Topical ophthalmic
Topical ophthalmic
Topical ophthalmic
SHJ - Maximum tolerated
Change from baseline in best corrected visual acuity
Change from baseline in best corrected visual acuity
Time frame: 3 days (Part 1) and 28 days (Part 2)
Incidence of Adverse Events
Incidence of Adverse Events
Time frame: 3 days (Part 1) and 28 days (Part 2)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Sep 2021, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.